<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109219">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01852864</url>
  </required_header>
  <id_info>
    <org_study_id>11/H0311/2</org_study_id>
    <nct_id>NCT01852864</nct_id>
  </id_info>
  <brief_title>Degarelix Before Radical Prostatectomy</brief_title>
  <official_title>A Study of the Early Biological Effects of Testosterone Suppression in Prostate Cancer Using Neoadjuvant Degarelix Prior to Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United kingdom: MHRA This study is not a CTIMP. MHRA have reviewed protocol and excluded need for further involvement</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The biological effects of castration on prostate cancers will be studies by administration
      of degarelix prior to radical prostatectomy.

      The effects will be studied by analysis of gene expression and immunohistochemistry focusing
      on markers of proliferation and apoptosis of samples taken at the time of radical
      prostatectomy (7-14 days after administration of degarelix).

      Tumours from patients treated with neo-adjuvant degarelix will be compared with tumours from
      patients who have not been medically castrated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>proliferative index defined by immunohistochemistry for ki67</measure>
    <time_frame>at surgery, 7-14 days after administration of degarelix</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gene expression levels measured by microarray</measure>
    <time_frame>At surgery 7-14 days after degarelix administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Degarelix treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>240mg degarelix s.c. injection to be administered 7-14 days prior to radical prostatectomy for high/intermediate risk prostate cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>240mg degarelix s.c. injection</intervention_name>
    <description>7-14 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.</description>
    <arm_group_label>Degarelix treated group</arm_group_label>
    <other_name>medical castration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intermediate/high risk prostate cancer

          -  Patient eligible for and wanting surgery

        Exclusion Criteria:

          -  Inability to consent

          -  Previous thromboembolism/arrhythymias

          -  contraindication to degarelix or surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Neal, BSc MS FRCS</last_name>
    <role>Study Chair</role>
    <affiliation>Cambridge University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Greg Shaw, MBBS MD FRCS</last_name>
    <phone>01223 331940</phone>
    <email>greg.shaw@cruk.cam.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Corcoran</last_name>
    <phone>01223348441</phone>
    <email>marie.corcoran@addenbrookes.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cambridge University Hopital NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB20QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Shaw</last_name>
    </contact>
    <investigator>
      <last_name>David Neal, MS FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 9, 2013</lastchanged_date>
  <firstreceived_date>May 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Greg Shaw</investigator_full_name>
    <investigator_title>Clinical Lecturer in Urology</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>testosterone</keyword>
  <keyword>castration</keyword>
  <keyword>degarelix</keyword>
  <keyword>proliferation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
